| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | CLIK1; STK35L1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human STK35 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于STK35抗体的3篇参考文献(文献标题与内容为示例性概括，实际文献需进一步验证)：
---
1. **标题**：*"STK35 regulates cell proliferation and migration in colorectal cancer via Hippo signaling pathway"*
**作者**：Li X et al.
**摘要**：研究利用STK35特异性抗体进行Western blot和免疫组化，发现STK35在结肠癌组织中高表达，并通过调控Hippo通路促进肿瘤细胞增殖和迁移。
---
2. **标题**：*"Characterization of STK35 expression in neuronal development using a novel polyclonal antibody"*
**作者**：Wang Y et al.
**摘要**：开发了一种兔源多克隆STK35抗体，验证其特异性后应用于小鼠脑组织免疫荧光，发现STK35在神经元分化早期阶段高表达，提示其参与神经发育调控。
---
3. **标题**：*"STK35 interacts with actin cytoskeleton and promotes invadopodia formation in breast cancer cells"*
**作者**：Chen H et al.
**摘要**：通过STK35抗体进行免疫共沉淀和共聚焦显微成像，证实STK35与肌动蛋白结合，促进乳腺癌细胞侵袭性伪足形成，增强转移能力。
---
**注意**：以上内容为基于STK35相关研究的常见方向模拟生成，实际文献需通过PubMed或Google Scholar以“STK35 antibody”为关键词检索确认。建议使用文献管理工具(如Zotero)获取准确引用信息。
The STK35 (Serine/Threonine Kinase 35) protein, also known as CLIK-1 or CILK1. is a member of the serine/threonine kinase family. It is encoded by the STK35 gene located on human chromosome 20q13.33. STK35 is structurally characterized by an N-terminal kinase domain and a C-terminal citron homology (CH) domain, which suggests roles in cytoskeletal regulation. Studies indicate its involvement in cellular processes such as mitosis, cell migration, and actin cytoskeleton dynamics. For instance, STK35 interacts with HSPBAP1 to modulate actin filament organization and may influence cancer cell proliferation and metastasis. Dysregulation of STK35 has been linked to diseases, including colorectal cancer, hepatocellular carcinoma, and inflammatory conditions, though its precise mechanisms remain under investigation.
Antibodies targeting STK35 are essential tools for detecting its expression, localization, and functional interactions. These antibodies (e.g., polyclonal or monoclonal clones like EPR19931) are validated for techniques such as Western blotting, immunofluorescence, and immunohistochemistry. They help identify STK35’s tissue-specific expression patterns, such as elevated levels in certain cancers or immune cells. Researchers also use these antibodies to explore STK35’s role in signaling pathways, including its potential cross-talk with the Hippo-YAP pathway. Specificity is confirmed via knockdown/knockout controls. Commercial antibodies are available from suppliers like Abcam, Sigma-Aldrich, and Cell Signaling Technology, often with species reactivity spanning humans, mice, and rats. Ongoing studies aim to clarify STK35’s dual roles as a context-dependent oncogene or tumor suppressor and its therapeutic potential.
×
